September 12th 2024
The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Larotrectinib Excites in TRK Fusion Cancers for Both Adult and Pediatric Patients
April 27th 2018When findings of larotrectinib, a pan-TRK inhibitor co-developed by Bayer and Loxo Oncology, that generated significant excitement for the treatment of both adult and pediatric patients with TRK fusion cancers, were presented during the 2017 ASCO Annual Meeting, the small molecule was lauded as a future standard of care for patients with advanced solid tumors harboring a TRK fusion.
Read More
Crizotinib Reaches 100% Disease Control Rate in ALK+ Inflammatory Myofibroblastic Tumors
April 16th 2018In a precision medicine success story, crizotinib (Xalkori) demonstrated a 50% objective response rate and a 100% disease control rate in patients with <em>ALK</em>-positive advanced, inoperable inflammatory tumors, in findings from the CREATE study presented at the 2018 AACR Annual Meeting.
Read More
Response Rate Tops 90% With Larotrectinib in TRK+ Pediatric Cancers
April 5th 2018According to findings from a phase I/II study published in <em>The Lancet Oncology</em>, there was an “unprecedented” objective response rate of 93% with larotrectinib in patients with TRK fusion–positive solid tumors.
Read More
Expert Discusses Promise of Novel Sarcoma Vaccine and Other Ongoing Research in the Field
March 30th 2018In an interview with <em>Targeted Oncology</em>, Pollack, assistant member, Clinical Research Division, assistant professor, Division of Oncology, University of Washington, and attending physician at Seattle Cancer Care Alliance, discussed some of the advancements his lab is making in the field of sarcoma.
Read More
New Drug Application Completed for Larotrectinib for Solid Tumors Harboring NTRK Gene Fusion
March 27th 2018The new drug application for larotrectinib (LOXO-101) for treatment of patients with locally advanced or metastatic solid tumors that harbor an NTRK gene fusion has been completed.
Read More
Biological Rationale Explained for Continued Investigation of Immunotherapy in Sarcomas
March 22nd 2018In the sarcoma field, the potential benefit of immunotherapy is currently challenged not only by the heterogeneity of each patient, but also by the heterogeneity of each histologic subtype. William D. Tap, MD, discussed the role for immunotherapy in patients with soft tissue sarcomas and gastrointestinal stromal tumors (GISTs) during a presentation at the 2018 ESMO Sarcoma & GIST Symposium.
Read More
Targeted Treatments Showing Early Efficacy in Sarcoma Subtypes
March 21st 2018Following in the footsteps of pazopanib and olaratumab, many targeted therapies are being studied in patients with soft tissue sarcomas to capitalize on the benefits of targeted therapies in sarcomas. Although chemotherapy-driven approaches remain the standard for treatment of sarcomas, many sensitivities to chemotherapies have appeared in patients with sarcoma subtypes. These patients may benefit from targeted therapy approaches.
Read More
Optimal Patient Selection for Denosumab in Giant Cell Tumor of Bone
January 24th 2018Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Instituto Ortopedico Rizzoli, discusses optimal patient selection for denosumab (Xgeva) in patients with giant cell tumor of bone.
Watch
Nivolumab/Ipilimumab Combo Induces Durable Responses in Advanced GISTs
January 22nd 2018Patients with heavily pretreated gastrointestinal stromal tumors responded to treatment with nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy), according to findings of a randomized phase II study presented at the 2018 Gastrointestinal Cancers Symposium.
Read More
Beckerle Awarded NCI Award for Research on Genetics of Cancer
January 17th 2018Mary C. Beckerle, PhD, has been awarded the Alfred G. Knudson Award in Cancer Genetics by the National Cancer Institute (NCI). She received her award at the NCI’s Maryland headquarters before delivering a lecture on tumor biology.
Read More
Novel Kinase Inhibitor Shows Encouraging Disease Control in Heavily Pretreated GIST
December 22nd 2017A novel kinase switch control inhibitor, DCC-2618, demonstrated an encouraging disease control rate (DCR) of 76% at 12 weeks in heavily pretreated patients with gastrointestinal stromal tumors (GIST) treated with a daily ≥100-mg dose, according to findings of a phase I first-in-human, dose-escalation trial.
Read More
Results for Denosumab in Patients With Giant Cell Tumor of Bone
December 20th 2017Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Instituto Ortopedico Rizzoli, discusses efficacy results for denosumab (Xgeva) in patients with giant cell tumor of bone (GCTB).
Watch
Larotrectinib Demonstrates 93% Response Rate in Pediatric Patients With Solid Tumors
December 20th 2017According to findings from the phase I SCOUT trial, the novel pan-TRK inhibitor larotrectinib (LOXO-101) achieved a 93% response rate in pediatric patients with <em>TRK</em> fusion–positive solid tumors.
Read More
Expert Discusses Promise of CMB305 Immunotherapy Regimen in Sarcoma
December 9th 2017CMB305, an immunotherapy regimen that generates and expands anti–NY-ESO-1 T cells, demonstrated a favorable survival rate compared with other approved agents for recurrent soft tissue sarcoma, according to results presented at the 2017 ASCO Annual Meeting.
Read More
Potential Seen for Entrectinib for Specific Patients With Sarcoma Harboring Genetic Rearrangements
December 8th 2017Confirmed responses were demonstrated in 3 patients with soft tissue sarcoma treated with entrectinib in the STARTRK-2 basket trial, according to the results of a case study presented at the 2017 Connective Tissue Oncology Society Annual Meeting that took place in Maui, Hawaii.
Read More
Pazopanib Regimen Misses Endpoints in Leiomyosarcoma Study
November 1st 2017Although the addition of pazopanib (Votrient) to gemcitabine in the second-line treatment of patients with metastatic or relapsed uterine or soft tissue leiomyosarcomas demonstrated disease control in the majority of patients, statistical endpoints were not met in the phase II UNICANCER SARCOMA 11 study, according to results reported at the 2017 ESMO Congress.
Read More
CMB305 Immunotherapy Regimen Demonstrates 83% OS Rate in Sarcoma, 1-Year Data Shows
September 14th 2017CMB305, an immunotherapy regimen that generates and expands anti-NY-ESO-1 T cells, demonstrated a favorable survival rate in patients with recurrent soft tissue sarcoma, compared with other agents approved for the disease.
Read More
Exploring the Efficacy of Pembrolizumab in Sarcoma Subtypes
August 31st 2017Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, and president of the Society for Immunotherapy of Cancer, discusses the SARC028 study, which explored the efficacy of pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas.
Watch
Recurrence-Free Survival in GIST at 90% With Long-Term Imatinib
August 22nd 2017Patients with intermediate- or high-risk gastrointestinal stromal tumors were less likely to experience recurrence after 5 years of treatment with imatinib, according to results from the phase II PERSIST-5 trial.
Read More
Trent Shares Treatment Considerations in 2 GIST Patient Cases
August 4th 2017Jonathan C. Trent, MD, PhD, recently discussed the treatment considerations he makes when treating patients with gastrointestinal stromal tumors (GIST). Trent discussed his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives dinner.
Read More
Separating Treatment of Leiomyosarcomas From STS Umbrella
July 19th 2017There are more than 70 subtypes that fall under the soft tissue sarcoma (STS) umbrella, according to the World Health Organization, and only account for approximately 1% of all cancers in adult patients. Yet, physicians continue to try to treat all sarcomas the same, making drug development for these types of tumors quite slow and frustrating.
Read More
Neoadjuvant Treatment With Imatinib Associated With High R0 Resection Rate in Gastric GIST
June 14th 2017Six to 9 months of treatment with neoadjuvant imatinib (Gleevec) was a promising treatment for patients with large gastric gastrointestinal stromal tumors (GIST), according to the results of a small multinational study in Asian patients.
Read More
Efficacy and Biomarker Results for Pembrolizumab in Soft Tissue and Bone Sarcomas
June 3rd 2017Lisa H. Butterfield, PhD, discusses efficacy and biomarker results of the phase II SARC028 study, which explored pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas, during the 2017 ASCO Annual Meeting.
Watch
Researchers Encouraged by Leiomyosarcoma Patient's Dramatic Response to Pembrolizumab
April 25th 2017Researchers at Dana-Farber Cancer Institute have identified an exceptional responder to pembrolizumab – a treatment-naïve patient with metastatic uterine leiomyosarcoma who had a complete tumor remission for more than 2 years on the PD-1 inhibitor.
Read More